Home - International News - Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value By Syndication Editor Feb 23, 2026 Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value International News 4 Total views No comments Syndication Editor Related Posts On-Chain Data Shows Bitcoin Far From Peak as Analyst Maps $240K Bull Case Trump’s call for 10% credit-card cap aims at banks’ crown jewels Comments (No) Leave a Reply Cancel Reply Save my name, email, and website in this browser for the next time I comment. Hide Comments
Comments (No)